mianserin

Mianserin, an H1 receptor reverse agonist, is a psychoactive compound in the tetracyclic antidepressant (TeCA) treatment family. Mianserin has antidepressant, antianxiety, antiemetic, hypotrophic, hypnotic and antihistamine effects, and can be used as a combination of norepinephrine and specific serotonin to treat depression.

Mianserin hydrochloride (Org GB 94) is a tetracyclic compound with antidepressant properties that blocks alpha-adrenergic, histamine H1, and certain serotonin receptors; it may cause drowsiness and hematological issues.

Nor mianserin hydrochloride, the demethylated derivative of Mianserin, functions as a serotonin antagonist. It is utilized in research related to disorders of serotonin metabolism and illnesses associated with histamine metabolism.

8-Hydroxy mianserin is a synthetic metabolite of Mianserin. It can serve as a precursor for the chemical synthesis of Mianserin metabolite derivatives.

Mianserin-D3 is a deuterated compound of Mianserin. Mianserin (T21428) has a CAS number of 24219-97-4. Mianserin, an H1 receptor reverse agonist, is a psychoactive compound in the tetracyclic antidepressant (TeCA) treatment family. Mianserin (T21428) has antidepressant, antianxiety, antiemetic, hypotrophic, hypnotic and antihistamine effects, and can be used as a combination of norepinephrine and specific serotonin to treat depression.

Mianserin-D3 hydrochloride is a deuterated compound of Mianserin Hydrochloride (TMSM-3431). Mianserin hydrochloride has a CAS number of 21535-47-7. Mianserin hydrochloride is a tetracyclic compound with antidepressant effects. it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors. It may cause drowsiness and hematological problems.

Mianserin hydrochloride (Standard) is a reference standard for research and analysis in studies involving Mianserin hydrochloride. Mianserin hydrochloride (Org GB 94) is a tetracyclic compound with antidepressant effects. it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors. It may cause drowsiness and hematological problems.

Mianserin-D3 Hcl (Standard) is a reference standard of Mianserin-D3 Hcl intended for quantitative analysis, quality control, and related biochemical research applications. Mianserin-d3 HCl is a deuterated compound of Mianserin HCl. Mianserin HCl has a CAS number of 21535-47-7. Mianserin hydrochloride is a tetracyclic compound with antidepressant effects. it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors. It may cause drowsiness and hematological problems.

N-Desmethylmianserin HCL (Standard) is a reference standard of N-Desmethylmianserin HCL intended for quantitative analysis, quality control, and related biochemical research applications.

Mirtazapine (6-Azamianserin) is a tetracyclic antidepressant with a somewhat unique mechanism of action. Mirtazapine therapy can be associated with transient asymptomatic elevations in serum aminotransferase levels and has been linked to rare instances of clinically apparent acute liver injury.

Mirtazapine-D3 is a deuterium labeled Mirtazapine. Mirtazapine is an inhibitor of 5-HT receptor .

(R)-Mirtazapine-D3 is a deuterium labeled  (R)-Mirtazapine (T12632). (R)-Mirtazapine is a antagonist of 5-HT3 receptor.

(R)-Mirtazapine ((R)-Org3770) is the R(-)-enantiomer of Mirtazapine, exhibiting anti-injury sensory properties in an animal model of acute thermal hyperalgesia. It functions as a 5-HT3 receptor antagonist and serves as a potential analgesic.

(S)-Mirtazapine ((S)-Org3770) is the S(+)-enantiomer of Mirtazapine, functioning as a selective 5-HT2 receptor antagonist with pro-nociceptive effects. It is commonly used in combination with the R(-)-enantiomer of Mirtazapine to study depression.

(S)-Mirtazapine-D3 is a deuterium labeled  (S)-Mirtazapine (T12632L). (S)-Mirtazapine is a stereoselective antagonist of 5-HT2 receptor. (S)-Mirtazapine is metabolized by CYP2D6 and CYP1A2.

Eltoprazine(DU28853) is a serenic or antiaggressive agent which as an agonist at the 5-HT1A and 5-HT1B receptors and as an antagonist at the 5-HT2C receptor.IC50 value:Target: 5-HT1A/1B agonist; 5-HT2C antagonistin vitro: The binding of [3H]eltoprazine to whole tissue sections was saturable and revealed an apparent dissociation constant (Kd) of 11 nM. Specific [3H]eltoprazine binding was completely displaced by 5-HT; conversely, unlabelled eltoprazine reduced [3H]5-HT binding to the levels of non-specific binding [1]. Eltoprazine evoked membrane changes that were similar to but much weaker than those induced by 5HT. Both the 5HT- and eltoprazine-evoked membrane hyperpolarizations were largely suppressed in the presence of spiperone [2].in vivo: eltoprazine is extremely effective in suppressing dyskinesia in experimental models, although this effect was accompanied by a partial worsening of the therapeutic effect of l-dopa. Interestingly, eltoprazine was found to (synergistically) potentiate the antidyskinetic effect of amantadine. The current data indicated that eltoprazine is highly effective in counteracting dyskinesia in preclinical models [3]. Rats were chronically treated with mianserin (10 mg/kg i.p.) or eltoprazine (1 mg/kg i.p.) and were tested in the elevated plus-maze test for anxiety. Mianserin and eltoprazine displayed opposite effects in the elevated plus-maze: mianserin induced anxiolytic-like effects, while eltoprazine showed anxiogenic-like ones [4]. [1]. Sijbesma H, et al. Eltoprazine, a drug which reduces aggressive behaviour, binds selectively to 5-HT1 receptor sites in the rat brain: an autoradiographic study. Eur J Pharmacol. 1990 Feb 20;177(1-2):55-66. [2]. Joels M, et al. Eltoprazine suppresses hyperpolarizing responses to serotonin in rat hippocampus. J Pharmacol Exp Ther. 1990 Apr;253(1):284-9. [3]. Bezard E, et al. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov Disord. 2013 Jul;28(8):1088-96. [4]. Rocha B, et al. Chronic mianserin or eltoprazine treatment in rats: effects on the elevated plus-maze test and on limbic 5-HT2C receptor levels. Eur J Pharmacol. 1994 Sep 1;262(1-2):125-31.